Corcept Therapeutics Incorporated
NASDAQ: CORT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Joseph K. Belanoff
- Employees
- 500
- Headquarters
- Menlo Park, United States
- IPO year
- 2004
- Market cap
- $8.6B
- Website
- https://www.corcept.com
Loading CORT…
Loading profile data…Frequently asked questions about CORT
What does Corcept Therapeutics Incorporated (CORT) do?
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone)...
Where does CORT trade?
Corcept Therapeutics Incorporated (CORT) trades on the NASDAQ Capital Market.
What sector is CORT in?
Corcept Therapeutics Incorporated (CORT) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Corcept Therapeutics Incorporated?
Joseph K. Belanoff is the chief executive officer of Corcept Therapeutics Incorporated (CORT).
Where is Corcept Therapeutics Incorporated headquartered?
Corcept Therapeutics Incorporated is headquartered in United States.
Does CORT pay a dividend?
Corcept Therapeutics Incorporated (CORT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CORT go public?
Corcept Therapeutics Incorporated (CORT) completed its initial public offering in 2004.